Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients With T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study

Oncologist - United States
doi 10.1634/theoncologist.2019-0103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Patients’ Preferences for Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Treatments in Japan

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2019English

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Clinical Medicine Insights: Oncology
Oncology
2015English

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Evaluation of the Incorporation of Recurrence Score Into the American Joint Committee on Cancer Eighth Edition Staging System in Patients With T1‐2N0M0, Estrogen Receptor‐Positive, Human Epidermal Growth Receptor 2‐Negative Invasive Breast Cancer: A Population‐Based Analysis

Oncologist
Cancer ResearchMedicineOncology
2019English

Distribution Patterns of 21-Gene Recurrence Score in 980 Chinese Estrogen Receptor-Positive, HER2-negative Early Breast Cancer Patients

Oncotarget
Oncology
2017English

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer Patients in Asia: Results From a Large, Multicountry Study

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy